FDA approves Abbott drug for psoriasisHumira approved to treat psoriasis, says Abbott; extra indication could add $500M to blockbuster's sales, analyst sales.NEW YORK (CNNMoney.com) -- The FDA approved Abbott's blockbuster drug Humira for yet another indication, psoriasis, the drugmaker said Friday. The extra indication could add at least $500 million in annual sales to Humira, which is expected to total $3 billion in 2007, said Phillip Nalbone, analyst for RBC Capital Markets, who was interviewed just prior to the announcement. Humira was already approved to treat psoriasis in Europe. In the U.S., Humira was already approved to treat four other diseases, including rheumatoid arthritis, psoriatic arthritis, an inflammation of the digestive tract called Crohn's disease and a spinal inflammation called ankylosing spondylitis. Abbott (ABT, Fortune 500) made the announcement after the close of trading. Abbott is the fourth-largest U.S. drugmaker in terms of annual sales, behind Johnson & Johnson (JNJ, Fortune 500), Pfizer (PFE, Fortune 500) and Merck (MRK, Fortune 500). |
Photo Galleries
When it comes to in-flight pampering, the amenity kits offered by these 10 airlines are the ultimate in luxury More
From a text therapy platform to apps that push you reminders to breathe, these self-care startups offer help on a daily basis or in times of need. More
From Uber's flying cars to the Hyperloop, these are some of the neatest transportation concepts in the works today. More
Sponsors
|
